Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603057 · ClinicalTrials.gov registry record
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 115
- Enrollment target
NCT00603057 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 115 participants.
The verdict
NCT00603057 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue. This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q SPECT), before treatment and then again during treatment to see if it helps predict how well the treatment works for your cancer and how well your lung functions during treatment. A Computerized Tomography (CT) will also be performed along with both of these procedures to help the researchers see clearly where your cancer or your healthy lung is located. The researchers are also doing blood tests in this study to look for markers in your blood and to see if it helps them in determining your risk of developing side effects from radiation to the lungs. The researchers hope that this study will help them in the future to design radiation treatment plans that provide the best treatment for each individual patient.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2007-05 |
| Est. Completion | 2015-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603057
The ClinicalTrials.gov registry entry for NCT00603057 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00603057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603057 about?
NCT00603057 is a clinical study titled "Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer". Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue. This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and V...
What is the current status of trial NCT00603057?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2007-05. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT00603057?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.